Founded in 1994, the Angiogenesis Foundation is the world’s first 501(c)(3) nonprofit organization dedicated to conquering disease using a new approach based on angiogenesis, the growth of new capillary blood vessels in the body. We have identified angiogenesis as the “common denominator” in society’s most feared diseases. Our focus on this underlying process of many different diseases makes our approach as a medical organization unique. The Foundation is the recognized, expert voice and champion of this new field of medicine.

Based in Cambridge, Massachusetts, the Angiogenesis Foundation works to help people lead healthier, longer lives by restoring balance to blood vessel growth. Through research, education, and advocacy — with patients, physicians, researchers, industry, payers, and government — we enable patients to gain access to safe and effective treatments coming from the angiogenesis field for cancer, blinding diseases, wounds, and many other serious diseases.

As a scientific organization, the Angiogenesis Foundation is independent of any individual, institution, or commercial entity. We are committed to helping people around the world benefit from the full promise of angiogenesis-based medicine, and to make life-, limb-, and vision-saving treatments available to everyone in need.


The Foundation organized the world’s first annual international research conference designed to bring together leaders in science, medicine, industry, and government to discuss advances against cancer and other diseases through angiogenesis-based treatment.

The Foundation has worked with the U.S. National Institutes of Health to develop systems for testing antiangiogenic activity in both new and old medications — including medications approved by the FDA for entirely unrelated medical conditions — that may be useful as cancer treatments.


The Foundation launched the world’s first research program to systematically identify and test antiangiogenic molecules present in dietary sources.

The Foundation helped to develop an antiangiogenic cream that cures skin cancers.

The Foundation demonstrated that therapeutic angiogenesis can be used to speed wound healing and regenerate lost tissues.

The Foundation was the to first to develop and study antiangiogenic treatments used by veterinarians to treat cancer in pet dogs, and other animals.


We envision that health in the 21st century will be revolutionized by medicines and foods that control angiogenesis. Through targeted approaches that inhibit or stimulate angiogenesis, we can find new ways to prevent, control, and cure disease. This approach has the potential to transform public health in the 21st century with the same sweeping impact that antibiotics had in the 20th century.

CMM-2010-LargeThe Angiogenesis Foundation has been a proud member of the Clinton Global Initiative since 2010.

CharityNav4StarsNewThe Angiogenesis Foundation has been awarded the highest 4-star rating from Charity Navigator, a premiere charity evaluator, for good governance, fiscal management, accountability and transparency, highlighting that the Foundation is worthy of public trust and the support of our generous donors.


As a 501(c)(3) nonprofit organization, the Angiogenesis Foundation is funded by charitable donations, grants, and philanthropic support from individuals, corporations, and foundations. View 990, aud financials.


Working with an international advisory board and a faculty of medical research experts, the Angiogenesis Foundation is speeding the progress of modern medicine, teaching doctors how to adopt 21st century treatments as they emerge, and laying the groundwork for major, future breakthroughs. Because angiogenesis plays a role in so many different diseases, the Foundation ‘cross-fertilizes’ knowledge from one disease research area to another, so that medical progress for many diseases can be catalyzed at once. Programs are centered on scientific collaboration, research, education, and advocacy.


The Foundation’s AngioTracker is the world’s largest continuously updated database for scientific and clinical research in the field, including clinical trials and data, and drug and device development.

The Foundation established the world’s first educational programs on angiogenesis aimed at practicing doctors and nurses, starting in 1997 and continuing today.

The Foundation designed a curriculum on angiogenesis that is taught to graduating medical school students each year at Dartmouth Medical School.

The Foundation assembled an international faculty of more than 600 medical and scientific experts to help us teach the world about angiogenesis.

The Foundation has guided the media’s understanding of angiogenesis, promoting accurate, informative coverage about new discoveries and breakthroughs to the public.